White House to Award $52.9 Million to Virginia Biotech Authority
The COVID-19 pandemic demonstrated a national health security vulnerability from heavy reliance on international manufacturing of critical pharmaceuticals and medical ...
Tag: Manufacturing Capacity
Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs
Internal Manufacturing Capabilities Expected to Support U.S. Pandemic Preparedness Tonix Pharmaceuticals will hold a ribbon-cutting ceremony at the company’s new ...
On Demand Pharmaceuticals Opens State-of-the-Art Manufacturing Facility in Maryland
Agile biomanufacturing technology incubated by DARPA reaches commercial facility milestone On Demand Pharmaceuticals, Inc. (ODP) announced on Feb. 15 the ...
DARPA Program Aims to Develop Fundamentals of Biomanufacturing in Space
The B-SURE (Biomanufacturing: Survival, Utility, and Reliability beyond Earth) program will leverage biological processes in resource limited environments. Imagine you ...
Rwanda and Senegal Will Host Africa’s First COVID-19 Vaccine Manufacturing Plants
The lack of vaccine production capacity in African countries has been the subject of much concern and hand-wringing in the ...
New Manufacturing Plant Gives Canada Domestic Production Capability for N95-Type Mask Filters
Medicom to open new plant to produce critical meltblown polypropylene filter raw material for masks. The company will also establish ...
DARPA Awards Nucleic Acids On-Demand (NOW) Contract to GE Research and Collaborators
The Defense Advanced Research Projects Agency (DARPA) has awarded project funding worth up to $41 million to GE Research and a ...
How Pharma is Changing to Produce a Pandemic Vaccine in Rapid Time
To bring COVID-19 under control a vaccine needs to be available to every nation, rich and poor – and it ...
AstraZeneca Teams with Oxford Biomedica to Shore Up COVID-19 Vaccine Manufacturing Capacity
Early manufacturing and scale up of viral vector based candidate for COVID-19 AstraZeneca and Oxford Biomedica this week announced a ...
GSK Announces Plans to Produce 1 Billion Doses of Pandemic Vaccine Adjuvant in 2021
Given the unprecedented need to develop COVID-19 vaccines, GSK has started manufacture of the adjuvant at risk. The company is ...
